title: Discovery of cryptophycin-1 and BCN-183577: examples of strategies and problems in the detection of antitumor activity in mice.
abstract: Historically, many new anticancer agents were first detected in a prescreen; usually consisting of a molecular/biochemical target or a cellular cytotoxicity assay. The agent then progressed to in vivo evaluation against transplanted human or mouse tumors. If the investigator had a large drug supply and ample resources, multiple tests were possible, with variations in tumor models, tumor and drug routes, dose-decrements, dose-schedules, number of groups, etc. However, in most large programs involving several hundred in vivo tests yearly, resource limitations and drug supply limitations have usually dictated a single trial. Under such restrictive conditions, we have implemented a flexible in vivo testing protocol. With this strategy, the tumor model is dictated by in vitro cellular sensitivity; drug route by water solubility (with water soluble agents injected intravenously); dosage decrement by drug supply, dose-schedule by toxicities encountered, etc. In this flexible design, many treatment parameters can be changed during the course of treatment (e.g., dose and schedule). The discovery of two active agents are presented (Cryptophycin-1, and Thioxanthone BCN 183577). Both were discovered by the intravenous route of administration. Both would have been missed if they were tested intraperitoneally, the usual drug route used in discovery protocols. It is also likely that they would have been missed with an easy to execute fixed protocol design, even if injected i.v.
authors.affiliation: Department of Internal Medicine, Wayne State University School of Medicine, Detroit, USA.
authors.forename: T H
authors.initials: TH
authors.lastname: Corbett
authors.forename: F A
authors.initials: FA
authors.lastname: Valeriote
authors.forename: L
authors.initials: L
authors.lastname: Demchik
authors.forename: N
authors.initials: N
authors.lastname: Lowichik
authors.forename: L
authors.initials: L
authors.lastname: Polin
authors.forename: C
authors.initials: C
authors.lastname: Panchapor
authors.forename: S
authors.initials: S
authors.lastname: Pugh
authors.forename: K
authors.initials: K
authors.lastname: White
authors.forename: J
authors.initials: J
authors.lastname: Kushner
authors.forename: J
authors.initials: J
authors.lastname: Rake
authors.forename: M
authors.initials: M
authors.lastname: Wentland
authors.forename: T
authors.initials: T
authors.lastname: Golakoti
authors.forename: C
authors.initials: C
authors.lastname: Hetzel
authors.forename: J
authors.initials: J
authors.lastname: Ogino
authors.forename: G
authors.initials: G
authors.lastname: Patterson
authors.forename: R
authors.initials: R
authors.lastname: Moore
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D047630:Depsipeptides; D004354:Drug Screening Assays, Antitumor / Q000379:methods*; D008297:Male; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000473:pathology; D010456:Peptides, Cyclic / Q000494:pharmacology*; D013892:Thioxanthenes / Q000494:pharmacology* / Q000633:toxicity; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; C110044:BCN 183577; D047630:Depsipeptides; D010456:Peptides, Cyclic; D013892:Thioxanthenes; C088419:cryptophycin